Evidence map›Paper›PMID 40996670›Full record

ReviewInfection2026

Post-tuberculosis lung disease: a guide for clinicians.

Giovanni Fumagalli, Jessica Mencarini, Irene Sini, Lucia Allavena, Marina Tadolini, Marco Mantero, Francesco Blasi, Niccolò Riccardi, Agostina Pontarelli, Pavilio Piccioni and 6 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Giovanni Fumagalli *TB Regional Reference Centre and Laboratory, ASST Grande Ospedale Metropolitano Niguarda-Villa Marelli Institute, Milan, Italy. giovanni.fumagalli@ospedaleniguarda.it.
Jessica Mencarini *StopTB Italia ODV, Milan, Italy.
Irene SiniDepartment of Physiopathology and Transplantation, University of Milan, Milan, Italy.
Lucia AllavenaDepartment of Physiopathology and Transplantation, University of Milan, Milan, Italy.
Marina TadoliniStopTB Italia ODV, Milan, Italy.
Marco ManteroDepartment of Physiopathology and Transplantation, University of Milan, Milan, Italy.
Francesco BlasiDepartment of Physiopathology and Transplantation, University of Milan, Milan, Italy.
Niccolò RiccardiTB Regional Reference Centre and Laboratory, ASST Grande Ospedale Metropolitano Niguarda-Villa Marelli Institute, Milan, Italy.
Agostina PontarelliStopTB Italia ODV, Milan, Italy.
Pavilio PiccioniStopTB Italia ODV, Milan, Italy.
Andrea CalcagnoStopTB Italia ODV, Milan, Italy.
Giovanni SotgiuStopTB Italia ODV, Milan, Italy.
Divya ShahFaculty of Medicine and Dentistry, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Luigi Ruffo CodecasaTB Regional Reference Centre and Laboratory, ASST Grande Ospedale Metropolitano Niguarda-Villa Marelli Institute, Milan, Italy.
Roberto ParrellaStopTB Italia ODV, Milan, Italy.
StopTB Italia ODV

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-tuberculosis lung disease (PTLD) is an increasingly recognized condition that significantly affects survivors' quality of life, creating disability and incrementing the risk of mortality. PTLD includes a spectrum of structural and functional lung impairments such as obstructive, restrictive, and mixed patterns, bronchiectasis, and pulmonary fibrosis that persist beyond microbiological cure. Global prevalence data highlight a heavy burden of PTLD, especially in high-incidence regions, driven by late diagnosis and suboptimal treatment. Functional and radiological evaluation remains critical for timely diagnosis, with spirometry and imaging revealing lasting abnormalities in a large proportion of TB survivors. Multidisciplinary care is essential and includes bronchodilator therapy, infections/complications management and prevention, pulmonary rehabilitation, and, in selected cases, surgical intervention. Despite increasing recognition, standardized diagnostic and therapeutic pathways for PTLD are still lacking, and data on optimal follow-up, rehabilitation strategies, and preventive measures remain limited. Prospective studies, better stratification tools, and patient education initiatives are urgently needed to reduce PTLD morbidity and mortality. This narrative review synthesizes current evidence on PTLD epidemiology, clinical evaluation and management while offering practical suggestions for clinicians taking care of people with TB and addressing research needs.

Indexed as

Lung DiseasesTuberculosisTuberculosis, PulmonaryHumansPrevalencePost TB lung diseaseTB managementTB sequelaeTuberculosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.